Document is current
Any future updates will be listed below
-
Authors
,
Nowak, Rebecca G. https://orcid.org/0000-0001-8404-4569
Nnaji, Chinedu H.
Dauda, Wuese
Mitchell, Andrew
Olaomi, Oluwole
Jibrin, Paul
Crowell, Trevor A.
Baral, Stefan D.
Ndembi, Nicaise
Charurat, Manhattan E.
Palefsky, Joel M.
Bentzen, Søren M.
Cullen, Kevin J.
-
Funding
Funding for this research was provided by:
National Cancer Institute (2P30CA134274-09S2, 5P30CA134274, 1K07CA225403)
Foundation for the National Institutes of Health (R01 MH099001, R01 AI120913, R01 MH110358)
Henry M. Jackson Foundation (W81XWH-11-2-0174, W81XWH-18-2-0040)
Fogarty International Center (D43TW010051)
U.S. President’s Emergency Plan for AIDS Relief (NU2GGH002099)
- License Information
-
More Information
Article History
Received: 16 August 2019
Accepted: 21 January 2020
First Online: 5 February 2020
Ethics approval and consent to participate
: The institutional review board at the Nigerian Federal Capital Territory Health Research Ethics Committee, the Clinical Research Committee at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, and the Institutional Review Board at the University of Maryland Baltimore reviewed and approved the research protocol. All participants provided written informed consent prior to enrollment and all data was de-identified.
: Not applicable.
: JMP has stock and ownership interests in Ubiome, Virion Therapeutics, VIR Biotechnology; has received honoraria from Janssen Pharmaceuticals, Vaccitech, Antiva Biosciences; has a consulting or advisory role for Antiva Biosciences, VIR Biotechnology, Vaccitech and Novan; receives research funding from Merck, Antiva Biosciences, VIR Biotechnology, CEL-SCI; and receives travel, accommodations and expenses from Merck, Vaccitech and Janssen. None of this relates to this specific work. All other authors have no competing interests.
